Veterans' Hormone Therapy: Systemic Gaps, Clinical Oversight, and Policy Pressures Fuel Testosterone Use
Original framing: “Hegseth Is Pushing Testosterone. The VA Has Already Struggled With the Treatment.” — The Intercept
Robust clinical trials demonstrate that exogenous testosterone suppresses spermatogenesis in a dose‑dependent manner, yet the VA's current guidelines lack mandatory baseline semen analysis and longitudinal follow‑up. Moreover, emerging research on selective androgen receptor modulators (SARMs) offers potential fertility‑sparing alternatives, but regulatory inertia stalls their adoption. Scientific evidence thus calls for stricter monitoring protocols and investment in newer therapeutics.
The push for testosterone within the VA reflects a confluence of institutional pressure, profit incentives, and cultural constructions of masculinity that overlook reproductive health and equity.
Historical precedents of rapid medical adoption without safeguards, coupled with scientific evidence of fertility suppression, demand a coordinated monitoring framework that integrates indigenous wisdom, cross‑cultural best practices, and artistic‑spiritual support. By foregrounding marginalized veteran voices and employing future‑oriented modeling, the VA can transition from a reactive, siloed system to a proactive, transparent network that preserves both physical and psychosocial wellbeing. The trickster insight reminds us that policies promising strength can paradoxically undermine the very foundations of continuity, urging a re‑imagining of care as stewardship rather than domination.